Eli Lilly's triple G agonist retatrutide has achieved weight loss of more than 28% in a new phase 3 trial that keeps it on course for regulatory filings later this year. The readout from the TRIUMPH-1 ...
There is only one approved therapy for lung disease non-cystic fibrosis bronchiectasis (NCFB) in the US and Europe – Insmed's ...
The Singapore Court of Appeal has retained an injunction against KBP Bio and its founder, Dr Huang Zhenhua, and ruled that a lawsuit brought by Novo Nordisk will be taken to arbitration. Last year, ...
Pfizer has upped the ante in the increasingly competitive market for pneumococcal vaccines with mid-stage clinical data for a ...
Galapagos' difficult year has continued with a decision to wind down its cell therapy business as it looks for deals that will deliver a "strong and sustainable future." The Belgian biotech's ...
A US district court has granted an injunction sought by Incyte on the launch of Sun Pharma's recently approved Leqselvi for alopecia areata. In a brief filing with the National Stock Exchange (NSE) of ...
A 'hybrid' therapy for Parkinson's disease developed by Remepy, combining a drug with a digital therapeutic, has shown ...
A report that the NHS is considering scaling back its recruitment drive and deploying greater use of AI to plug the gap has ...
UK-based GHO and CBC Group of Singapore – have announced a merger to create a massive player in the category with $21 billion ...
The WHO has held a closed expert meeting to identify potential vaccines for the Bundibugyo species of Ebola that is causing ...
A phase 2 trial of Sanofi's experimental therapy for alpha-1 antitrypsin deficiency (AATD) has raised the hope of an ...
Fresh from agreeing a wide-ranging alliance with Regeneron worth up to $2.3 billion, Parabilis Medicines has decided to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results